Persona Partial Knee Clinical Outcomes Study
Status: | Recruiting |
---|---|
Conditions: | Arthritis, Osteoarthritis (OA), Orthopedic |
Therapuetic Areas: | Rheumatology, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 9/9/2018 |
Start Date: | February 8, 2017 |
End Date: | July 2029 |
Contact: | Scott Abshagen, RN, BS |
Email: | scott.abshagen@zimmerbiomet.com |
Phone: | 574-371-9782 |
The primary objective of this study is to obtain implant survivorship and clinical outcomes
data for the commercially available Persona Partial Knee System.
data for the commercially available Persona Partial Knee System.
The study design is a prospective, multicenter, noncontrolled study of the commercially
available Persona Partial Knee. The study will require each site to obtain IRB approval prior
to study enrollment. All potential study subjects will be required to participate in the
Informed Consent Process.
All study subjects will undergo preoperative clinical evaluations prior to their partial knee
arthroplasty. Investigators will collect clinical data for a required 2 years with the option
to continue follow-up assessment up to 10 years. Follow-up clinical visits include 3 months,
1 year, 2, 5, and 10 years post-operatively.
The primary objective of this study is to obtain implant survivorship and clinical outcomes
data for the commercially available Persona Partial Knee System. The assessments will
include: implant survivorship based on revision with removal of the study device; safety
based on incidence and frequency of adverse events; and clinical performance measured by
overall pain and function, quality of life data, radiographic parameters, and survivorship.
available Persona Partial Knee. The study will require each site to obtain IRB approval prior
to study enrollment. All potential study subjects will be required to participate in the
Informed Consent Process.
All study subjects will undergo preoperative clinical evaluations prior to their partial knee
arthroplasty. Investigators will collect clinical data for a required 2 years with the option
to continue follow-up assessment up to 10 years. Follow-up clinical visits include 3 months,
1 year, 2, 5, and 10 years post-operatively.
The primary objective of this study is to obtain implant survivorship and clinical outcomes
data for the commercially available Persona Partial Knee System. The assessments will
include: implant survivorship based on revision with removal of the study device; safety
based on incidence and frequency of adverse events; and clinical performance measured by
overall pain and function, quality of life data, radiographic parameters, and survivorship.
Inclusion Criteria:
- Patient is at least 18 years of age
- Patient qualifies for knee arthroplasty based upon physical exam and medical history,
and meets the approved indications for use of the Persona Partial Knee system.
- Patient has participated in a study-related Informed Consent process
- Patient is willing and able to provide written Informed Consent by signing and dating
the IRB/EC approved Informed Consent form
- Patient is willing and able to complete scheduled study procedures and follow-up
evaluations
- Independent of study participation, patient is a candidate for the commercially
available Persona Partial Knee, implanted in accordance with product labeling
Exclusion Criteria:
- Patient is currently participating in any other surgical intervention studies or pain
management studies
- Infection, sepsis, and osteomyelitis
- Rheumatoid arthritis or other forms of inflammatory joint disease
- Insufficiency of the collateral, anterior or posterior cruciate ligaments which would
preclude stability of the device
- Full thickness damage to the weight bearing area of the contralateral compartment
- Uncooperative patient or patient with neurologic disorders who is incapable of
following directions
- Insufficient bone stock to provide adequate support and/or fixation to the prosthesis
- Metabolic disorders which may impair bone formation
- Osteomalacia
- Distant foci of infections which may spread to the implant site
- Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram
- Vascular insufficiency, muscular atrophy, neuromuscular disease
- Incomplete or deficient soft tissue surrounding the knee
- Charcot's disease
- Fixed varus deformity (not passively correctable) of greater than 15 degrees
- Fixed flexion deformity (not passively correctable) of greater than 15 degrees
- Patient is pregnant or considered a member of a protected population (e.g., prisoner,
mentally incompetent, etc.)
We found this trial at
11
sites
1910 Blanding Street
Columbia, South Carolina 29201
Columbia, South Carolina 29201
Principal Investigator: James A O'Leary, MD
Phone: 803-256-4107
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
Principal Investigator: Samuel K Tabet, MD
Phone: 505-724-4300
Click here to add this to my saved trials
10215 Fernwood Road
Bethesda, Maryland 20817
Bethesda, Maryland 20817
Principal Investigator: Christopher J Cannova, MD
Phone: 301-530-1010
Click here to add this to my saved trials
1 Orthopedics Drive
Beverly, Massachusetts 01960
Beverly, Massachusetts 01960
Principal Investigator: Ira K Evans, MD
Phone: 978-818-6433
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Denis Nam, MD
Phone: 312-432-2418
Click here to add this to my saved trials
Fremont, California 94538
Principal Investigator: Alexander P Sah, MD
Phone: 510-818-7200
Click here to add this to my saved trials
660 Golden Ridge Road
Golden, Colorado 80401
Golden, Colorado 80401
Principal Investigator: Jared RH Foran, MD
Phone: 303-233-1223
Click here to add this to my saved trials
2320 Freeway Drive
Mount Vernon, Washington 98273
Mount Vernon, Washington 98273
Principal Investigator: Richard Williamson, MD
Phone: 360-814-6827
Click here to add this to my saved trials
New Castle, Indiana 47362
Principal Investigator: Lindsey R Rolston, MD
Phone: 765-521-7385
Click here to add this to my saved trials
1350 Kirts Boulevard
Troy, Michigan 48084
Troy, Michigan 48084
Principal Investigator: Donald M Knapke, MD
Phone: 248-244-9426
Click here to add this to my saved trials